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Abstract
BRCA1 and BRCA2 are the most well-known breast cancer susceptibility genes. Additional genes involved in DNA repair
have been identified as predisposing to breast cancer. One such gene, RAD51C, is essential for homologous recombination
repair. Several likely pathogenic RAD51C mutations have been identified in BRCA1- and BRCA2-negative breast and ovarian
cancer families. We performed complete sequencing of RAD51C in germline DNA of 286 female breast and/or ovarian
cancer cases with a family history of breast and ovarian cancers, who had previously tested negative for mutations in
BRCA1 and BRCA2. We screened 133 breast cancer cases, 119 ovarian cancer cases, and 34 with both breast and ovarian
cancers. Fifteen DNA sequence variants were identified; including four intronic, one 59 UTR, one promoter, three
synonymous, and six non-synonymous variants. None were truncating. The in-silico SIFT and Polyphen programs were
used to predict possible pathogenicity of the six non-synonomous variants based on sequence conservation. G153D and
T287A were predicted to be likely pathogenic. Two additional variants, A126T and R214C alter amino acids in important
domains of the protein such that they could be pathogenic. Two-hybrid screening and immunoblot analyses were
performed to assess the functionality of these four non-synonomous variants in yeast. The RAD51C-G153D protein
displayed no detectable interaction with either XRCC3 or RAD51B, and RAD51C-R214C displayed significantly decreased
interaction with both XRCC3 and RAD51B (p,0.001). Immunoblots of RAD51C-Gal4 activation domain fusion peptides
showed protein levels of RAD51C-G153D and RAD51C-R214C that were 50% and 60% of the wild-type, respectively. Based
on these data, the RAD51C-G153D variant is likely to be pathogenic, while the RAD51C- R214C variant is hypomorphic of
uncertain pathogenicity. These results provide further support that RAD51C is a rare breast and ovarian cancer
susceptibility gene.
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Introduction
Breast cancer is the most common cancer worldwide and the
second leading cause of cancer death among women in the United
States [1]. Familial cases of breast cancer comprise approximately
5–10% of all breast cancer, whereas familial ovarian cancer
accounts for 10% of invasive ovarian cancer [2,3]. BRCA1 and
BRCA2 are the most well-known genes predisposing to breast
cancer. Mutations in CHEK2, ATM, BRIP1, and PALB2, genes
also involved in genome maintenance and homologous recombi-
nation, have been identified as predisposing to breast cancer;
however they only account for a small portion of the hereditary
cases [4].
Recently, RAD51C, essential for homologous recombination
repair, has been reported to be a rare hereditary breast and
ovarian cancer susceptibility gene and several pathogenic RAD51C
mutations have been identified in BRCA1- and BRCA2-negative
hereditary breast and ovarian cancer families (HBOC) [5]. At the
same time, a biallelic mutation in RAD51C was reported in a
family with multiple severe abnormalities characteristic of Fanconi
Anemia [6]. Several pathogenic variants were observed in five
studies [5,7,8,9,10] with all in HBOC families or in ovarian cancer
cases. No clearly pathogenic mutations were detected in two other
studies [11,12]. Thus, there are multiple studies and evidence that
RAD51C is a rare ovarian cancer predisposition gene important in
both breast and ovarian cancers in HBOC families. More studies
are needed to determine its penetrance and the role it plays in
these cancers.
In the current study, we screened for RAD51C mutations in a
clinic-based set of women with breast and/or ovarian cancers in
families with HBOC who had previously tested negative for
BRCA1 and BRCA2 mutations.
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Mutation screening
We found 15 variants, including four intronic, one 59
untranslated region (UTR), one promoter, three synonymous,
and six non-synonymous variants (Table 2). None of the variants
caused protein truncation. Of the fifteen variants, six had been
previously identified and had dbSNP rs numbers, and nine were
novel.
Functional Analyses
Of the six non-synonomous variants, SIFT and Polyphen
predicted that two are likely pathogenic (G153D and T287A),
based on the degree of conservation of the affected residue. An
additional two non-synonomous variants (A126T and R214C)
alter amino acids in conserved domains of the protein, and
therefore could possibly disrupt function (Table 2). It had
previously been shown through yeast two-hybrid analysis that
human RAD51C interacts with human XRCC3 and RAD51B
[13,14], and that these proteins form complexes in vivo
[14,15,16,17]. We tested whether these missense mutations
affected the interaction between RAD51C and both XRCC3
and RAD51B by yeast two-hybrid analysis. RAD51C-A126T
displayed a level of interaction with both XRCC3 and RAD51B
that was not significantly different from wild-type (p=0.88 and
0.48, respectively), while interactions between RAD51C-G153D
and these proteins were undetectable (p,0.0001 for both)
(Figure 1). RAD51C- R214C displayed significant decreases in
interaction with both XRCC3 (p=0.0008) and RAD51B
(p=0.0002), while RAD51C-T287A displayed a slight but
significant decrease in association with XRCC3 (P=0.034 ), but
a level of interaction with RAD51B that was not significantly
different from wild-type (p=0.11).
One possible explanation for the decreased levels of interaction
conferred by RAD51C-G153D, RAD51C-R214C, and RAD51C-
T287A is that these mutationsresult in reduced steady-state levels of
RAD51C. This could be caused by a reduction in gene expression
or reduced protein stability due to improper folding. To rule out the
possibility that significant differences in the steady-state levels of the
mutant proteins in yeast could account for the observed differences
in the two-hybrid assay results, we examined the steady-state levels
of the wild-type and mutant RAD51C-Gal4activationdomain(AD)
fusion peptides by western blot analysis using an antibody against
the Gal4 AD (Figure 2). Blots were also probed with an antibody
against b-actin as a control for equal loadingof protein. As shown in
Figure 2, the RAD51C-G153D mutation had little effect on
RAD51C-AD in strains that were expressing XRCC3- and
RAD51B-Gal4 DNA binding domain (BD) fusions respectively.
Thereduction(,50%)inthestrainalsoexpressingXRCC3wasnot
sufficient to explain the complete absence of interaction with the
protein indicated by the two-hybrid assay (Figure 1). Similarly, the
RAD51C-R214C mutation had little effect on the RAD51C-AD in
the strains that were also expressing XRCC3-BD and RAD51B-
BD, respectively (Figure 2). Neither RAD51C-A126T nor RAD51C-
T287A conferred detectable changes in the levels of RAD51C-AD.
Therefore, there wasno evidence for gross changes of the stability of
RAD51C-AD in these yeast strains.
Pedigree analysis
RAD51C-R214C is an exon 4 mutation and was found in an
African-American proband who was diagnosed with stage IIA,
ER/PR positive, Her2/Neu positive, infiltrating ductal carcinoma
of the breast at age 42, and who had a family history of both breast
and ovarian cancers on her mother’s side of the family (Figure 3A).
One great aunt on her grandfather’s side was diagnosed with
ovarian cancer at age 50 years and another great aunt with breast
cancer was diagnosed at age 60 years. A first cousin once removed
on her grandmother’s side was diagnosed with breast cancer at age
67 years. We did not observe this variant in a set of 192 African-
American women screened for mutations in RAD51C (data not
presented). RAD51C-G153D is an exon 3 mutation identified in a
Non-Hispanic White proband who was diagnosed with breast
cancer at age 60 and with stage IV, serous carcinoma of the ovary
at age 79. Her sister was diagnosed with breast cancer at age 73
(Figure 3B). No additional family DNAs were available to
investigate co-segregation of the mutations with cancer.
Discussion
It has been well established that deficient DNA repair and
specifically, homologous recombination plays a critical role in
cancer susceptibility. RAD51C is involved in two specific
subcomplexes, one with XRCC2, RAD51B, and RAD51D, and
the other with XRCC3 [18], and has multiple functions in the
DNA damage response and the maintenance of genomic stability
[19]. Interestingly, RAD51C is located in chromosomal region
17q23, which is amplified in primary breast cancer tumors [20],
but it hadn’t been investigated previously as a susceptibility locus
for breast cancer. Further confirmation of its role in breast tumors
was the discovery that the MCF-7 breast cancer cell line contains a
RAD51C-ATXN7 fusion gene consisting of RAD51C exons 1–7 and
ATXN7 exons 6–13 [21]. Other RAD51 gene family members had
been associated with increased risk of breast cancer [18], but there
had been no reports implicating RAD51C.
To further investigate the role of RAD51C as an HBOC
predisposition gene, we performed complete sequencing of
RAD51C to screen for mutations in 286 BRCA1- and BRCA2-
negative breast and/or ovarian cancer cases with a family history
of breast and ovarian cancer. Fifteen variants were identified, of
which we selected four non-synonymous variants for functional
studies; RAD51C-G153D and RAD51C-T287A because they alter
highly conserved amino acid residues (predicted to be pathogenic
by SIFT and Polyphen), RAD51C-A126T because it alters an
amino acid in the Walker A box, and RAD51C-R214C because it
alters an amino acid that separates a beta-strand from an alpha-
helix. Yeast two-hybrid and immunoblot assays indicated that the
RAD51C-T287A and RAD51C-A126T mutations do not substan-
tially alter either the ability of RAD51C to interact with its
companion proteins or its steady-state level, consistent with the
results of the functional assays of Meindl at al. [7]. Furthermore,
these two variants have been identified multiple times in other
studies [5,7,8,10,11,12], suggesting that they are benign polymor-
phisms. However, the results of the yeast two-hybrid and
immunoblot assays were consistent with RAD51C-G153D being
a pathogenic mutation as it led to undetectable levels of interaction
between RAD51C and both XRCC3 and RAD51B, but did not
markedly change levels of RAD51C. We hypothesize that the
RAD51C-G153D mutation critically alters the ability of RAD51C
to interact with XRCC3 and RAD51B, although it is not in a
region of known secondary structure. RAD51C-R214C may be a
hypomorphic mutation of uncertain clinical significance. Small but
significant reductions in interaction between RAD51C and both
XRCC3 and RAD51B were observed, but there were no marked
changes in the steady-state level of RAD51C (Figures 1 and 2).
Unfortunately, there were no additional samples in the families in
order to investigate cosegregation with breast and ovarian cancer
or tumor tissue to determine if there was loss of heterozygosity of
the wild-type allele.
RAD51C Germline Mutations
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ovarian cancer (HBOC) predisposition gene by Meindl et al. [5].
After discovering that it was associated with Fanconi anemia [6],
they screened for mutations in RAD51C in 1100 hereditary breast
(HBC) and HBOC families, hypothesizing that it would be similar
to BRIP1 and BRCA2 in which biallelic mutations cause Fanconi
anemia and monoallelic mutations cause HBOC. They identified
14 monoallelic germline mutations of which 6 were considered
pathogenic [5]. The mutations were only identified in cases from
families with both breast and ovarian cancers (6/480) and in no
cases from families with only breast cancer (0/620) [5]. In a
Spanish study of 492 BRCA1- and BRCA2 tested-negative breast
cancer patients with family history of breast and/or ovarian
cancer, they identified 12 variants, of which one was clearly
pathogenic in the subset of 106 cases with a family history of both
breast and ovarian cancers [7]. Interestingly, the one case was of
Swedish origin, and this mutation was recently reported in an
ovarian case in a study of Swedish and Finnish familial breast
cancer cases and unselected ovarian cancer cases [8]. That study
also reported a second clearly pathogenic mutation in an HBOC
breast cancer case. In a recent Finnish study, two recurrent
deleterious mutations were identified, and specifically in those with
a personal or family history of ovarian cancer [10]. In a Chinese
study of 275 women from HBOC families, two possibly
pathogenic mutations were found [9]. In two additional studies
of 454 and 92 breast and/or ovarian cancer cases from HBOC
families, no pathogenic mutations were found [11,12]. RAD51C
mutations appear to be rare mutations that predispose to ovarian
cancer, as well as to breast cancer but only in families with ovarian
cancer.
Figure 1. Effect of RAD51C point mutations on the interaction with XRCC3 and RAD51B. (A) Yeast two-hybrid assays were performed with
XRCC3 in the DNA-binding domain vector and either wild-type or site-specifically mutated RAD51C in the activating domain vector. (B) Yeast two-
hybrid assays were performed with RAD51B in the DNA-binding domain vector and the RAD51C variants in the activating domain vector. Results from
liquid ONPG assays are the average of 5–7 different transformants performed in triplicate, with the standard error of the mean. * : P,0.05 and
** :P#0.001 using the student T-test.
doi:10.1371/journal.pone.0025632.g001
RAD51C Germline Mutations
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one hypomorphic mutation. These unique mutations had not been
seen in previous studies, in this case series or in a case series of
African Americans. The likely pathogenic mutation G513D
mutation was found in a woman with both breast and ovarian
cancers and the likely hypomorphic mutation, R214C mutation
was found in an African-American woman with breast cancer and
a family history of ovarian cancer. Our results provide further data
that RAD51C is a predisposition gene for hereditary breast and
ovarian cancers. Future studies investigating larger, multi-ethnic
populations of ovarian cancers, and that include sampling of
family members, are needed to better understand the role of
RAD51C in ovarian cancers and HBOC.
Methods
Ethics Statement
All research involving human participants was approved by the
City of Hope Institutional Review Board (IRB#96144). After a
complete description of the study to the subjects, written, informed
consent was obtained.
Study Subjects
The study population was women diagnosed with breast and/or
ovarian cancers seen for genetic cancer risk assessment (GCRA) in
The City of Hope Clinical Cancer Genetics Community Research
Network and enrolled in an Institutional Review Board-approved
registry protocol (IRB#96144) between October 1996 and May
2010. The Clinical Cancer Genetics Community Research
Network is a collaboration of genetic cancer risk assessment
programs. All of the programs follow standard genetic cancer risk
assessment protocols, including counseling by experienced clini-
cians, and assembly of a 4–5 generation pedigree with detailed
cancer histories. A detailed family history of at least three
generations was obtained at the initial GCRA visit and each
patient donated a blood sample after written, informed consent.
Eligibility criteria for the current study included (1) a diagnosis
of breast and/or ovarian cancer, (2) a previous negative test result
for pathogenic germline mutations in BRCA1 and BRCA2, and (3)
a family history of at least one breast cancer and/or ovarian
cancer in a first-, second-, or third-degree relative. A total of 133
breast cancer cases, 119 ovarian cancer cases, and 34 cases with
both breast and ovarian cancer were eligible. All cases were
unrelated. Clinical diagnosis and race/ethnicity information are
described in Table 1.
DNA Sequencing of RAD51C
The nine primer pairs used to amplify the 9 exons and intron-
exon boundaries of RAD51C were described in Meindl et al [5].
Amplicons were sequenced in both directions using the BigDye
terminator 3.1 cycle sequencing kit with sequencing performed on
an 3130 Sequencer from Applied Biosystems Inc. (ABI).
Sequencing traces were analyzed using SeqScape 2.5 (ABI) and
by manual inspection.
Figure 2. Immunoblots of RAD51C in the yeast strains used for
the two-hybrid analysis. The upper panel shows the immunoblot
blot analysis of the yeast strains containing human XRCC3 and RAD51C
while the lower panel shows the same immunoblots from the yeast
strains used in the RAD51B and RAD51C analysis. The RAD51C-Gal4
fusion peptides were identified using an anti-Gal4 monoclonal
antibody. The same lysates were probed with an antibody against b-
actin as a control for equal loading of protein.
doi:10.1371/journal.pone.0025632.g002
Figure 3. Pedigrees of cases carrying the R214C and G153D mutations. (A) R214C: African-American proband diagnosed with stage IIA, ER/
PR positive, Her2/Neu positive, infiltrating ductal carcinoma of the breast at age 42 years. (B) G153D: Non-Hispanic Caucasian proband diagnosed
with breast cancer at age 60 years and with stage IV, serous carcinoma of the ovary at age 79 years.
doi:10.1371/journal.pone.0025632.g003
RAD51C Germline Mutations
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25632Prediction of functional mutations
The amino-acid substitution prediction programs, SIFT
(http://sift.jcvi.org/) and Polyphen (http://genetics.bwh.harvard.
edu/pph/), were used to predict the possible impact of non-
synonymous variants. The algorithms in both programs use
evolutionary conservation across species, as well as reference
sequence alignments, physiochemical differences and the proxim-
ity of the substitution to predicted functional domains and/or
structural features.
Plasmid construction. Yeast two-hybrid plasmid constructs
for full-length human RAD51B, RAD51C and XRCC3 cDNAs were
the kind gift of Dr. David Schild (Lawrence Berkeley National
Laboratory; Berkeley, CA). The RAD51B and XRCC3 cDNAs
were cloned into the Gal4 DNA-binding domain vector pGBT9,
and the RAD51C cDNA was cloned into the transcriptional
activation domain vector pGAD424 both of which were the kind
gift of Dr. Stan Fields (HHMI University of Washington; Seattle,
WA). The Phusion Site-directed Mutagenesis Kit (Finnzymes/
New England Biolabs) was used for mutagenesis, and each
mutated construct was sequenced across the entire insert to
confirm the mutation.
Yeast two-hybrid analysis. The Matchmaker yeast two-
hybrid kit was used according to the manufacturer’s instructions
(Clontech). The yeast strain Y187 was co-transformed with either
the human XRCC3 or RAD51B cDNAs cloned into pGBT9 and
the RAD51C cDNA into pGAD424 and plated on synthetic
medium lacking leucine and tryptophan. To quantitate the
interactions between any two protein combinations, liquid b-
galactosidase assays were performed on yeast colonies containing
both pGBT9 and pGAD424 derivatives using O-nitrophenol-b-D-
galactopyranoside (ONPG) as a substrate as outlined in the yeast
protocols handbook (Clontech). Briefly, for each construct, single
doubly transformed yeast colonies were inoculated into five ml of
synthetic medium lacking leucine and tryptophan and grown
overnight at 30uC. One ml of the overnight yeast culture was
transferred to a culture tube containing four ml of medium
containing yeast extract, peptone, dextrose, and adenine (YPDA)
and grown with shaking for five h at 30uC. Culture densities were
assessed by OD600. Three 1.5 ml aliquots of each sample
(triplicates) were centrifuged for two min at 10,000 g and washed
with one ml of Z buffer (16.1 g/l NaHPO4?7H2O, 5.5 g/l
NaHPO4?H2O, 0.75 g/l KCl, 0.246 g/l MgSO4?7H2O). Cells
were then resuspended in 100 ml of Z buffer and were subjected to
three freeze–thaw cycles. To each tube, 700 ml of Z buffer plus b-
mercaptoethanol and 160 ml of 4 mg/ml ONPG was added and
the tube was incubated at 30uC until a yellow color developed.
Table 1. Characteristics of tested individual in family.
Cancer Diagnosis Total
Non-Hispanic
White
N( % )
Hispanic
N( % )
Other
N( % )
Missing
N( % )
Age of onset of first primary
diagnosis in years
(mean ± SD)
Breast and Ovarian 43 7 (20.6) 6 (17.7) 16 (18.6) 14 (41.2) 52.6613.7
Breast 119 52 (43.7) 12 (10.1) 6 (5.1) 49 (41.2) 51.4613.1
Ovarian 124 54 (40.6) 12 (9.0) 11 (17.1) 47 (35.3) 42.966.7
Total 286 113 (39.5) 30 (10.5) 33 (11.5) 110 (38.5) 47.6611.5
doi:10.1371/journal.pone.0025632.t001
Table 2. Variants identified through sequencing.
Variant RS# Location Effect* Amino Acid
Functional
prediction
Observed
MAF
Hapmap
MAF Previously Observed
c.1-118G.A rs16943176 Promoter 0.155 0.203 [12]
c.1-26C.T rs12946397 59 UTR 0.166 0.207 [10,12]
c.186A.G rs28363303 Exon 2 S Q62Q 0.002 0.006 [12]
c.336G.C – Exon 2 S G112G 0.002
c.376G.A rs61758784 Exon 2 NS A126T Tolerated 0.005 No data [5,7,8,11]
c.404+72ins9bp – Intron 2 0.002
c.458G.A – Exon 3 NS G153D Damaging 0.002
c.564G.T – Exon 3 NS K188N Tolerated 0.002
c.572-17G.T – Intron 3 [7]
c.640C.T – Exon 4 NS R214C Tolerated 0.002
c.706-18T.C rs56401264 Intron 4 0.002 No data [9]
c.859A.G rs28363317 Exon 6 NS T287A Damaging 0.016 0.017 [5,7,8,10,11,12]
c.871G.A – Exon 6 NS D291N Tolerated 0.002
c.904+34T.C – Intron 9 [7,9,10,12]
c.1062A.G – Exon 9 S A354A 0.005
*synonomous (S) or non-synonomous (NS) amino acid change.
MAF=minor allele frequency.
doi:10.1371/journal.pone.0025632.t002
RAD51C Germline Mutations
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the samples were centrifuged at 14,000 rpm for 10 min. Product
formation was assessed by determining OD420 at appropriate
intervals (16 h for the XRCC3+RAD51C assays and 30 min for
the RAD51B+RAD51C assays) and units of b-galactosidase (per ?)
were calculated. The results from each combination represent the
average of five to seven separate co-transformants assayed in
triplicate, with standard error of the mean. P values were
determined using the student T-test with Microsoft Office Excel
software.
Immunoblot analysis. Fifty ml cultures of yeast containing
the plasmids of interest were grown to mid log phase (OD600=0.6
to 0.7) in synthetic medium lacking leucine and tryptophan. The
cells were collected by centrifugation at 4uC for for min at
5,000 rpm in a Sorvall SA600 rotor, washed twice in ice-cold PBS,
and resuspended in 600 ul lysis buffer (50 mM HEPES, pH 7.5,
140 mM NaCl, 1% Triton-X100, 0.1% sodium deoxycholate,
1 mM EDTA, 16Complete Protease Inhibitor Cocktail (Roche),
and 10 mM PMSF). An equal volume of glass beads was added
and each sample was vortexed five times for 30 sec followed by
centrifugation at 4uC to remove the cell debris. The protein
concentrations were determined using the Bradford protein assay
(Pierce) and the lysates were stored at 280 uC. Prior to
electrophoresis, an appropriate volume of cell lysate was diluted
in 56 SDS sample loading buffer (250 mM Tris-HCl pH 6.8,
50% Glycerol, 4% SDS, 250 mM DTT, 0.1% Bromophenol Blue)
and boiled for 5 min. Total cellular protein (15 mg) was
fractionated by SDS/PAGE on NuPAGE 4–12% gradient gels
(Invitrogen) and electrotransferred onto PVDF membranes. The
membranes were probed with antibodies directed against the Gal4
activation domain (Clontech) or b-actin (mAbcam 8224, Abcam).
Following incubation with primary antibody, detection was carried
out using horseradish peroxidase-conjugated goat anti-mouse
secondary antibody (Thermo Scientific). Membranes were
incubated with Supersignal West Fempto substrate (Pierce),
followed by exposure with BioMax XAR film (Kodak).
Quantification of immunoblot signals was performed by
densitometry using the GS-800 Calibrated Densitometer (Bio-
Rad Laboratories).
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